Metabolic improvements: blood sugar, A1C, cholesterol, and blood pressure Weight loss is visible
Reddys Laboraties, began landing in Canadian pharmacies the week of May 18
Study details : 1197 patients with MASH and fibrosis stage 2 or 3 were recruited and randomized in a 2:1 ratio of semaglutide or placebo for 240 weeks
This article reports what has been documented, not what should be done
Safety : While all GLP-1 agonists share similar gastrointestinal side effects, such as nausea and diarrhea, semaglutide is generally well-tolerated, though higher doses can increase nausea
In January of 2025, the FDA also approved Ozempic to treat chronic kidney disease in diabetic patients